Alto Pharmacy, a San Francisco, CA-based digital pharmacy, raised $50m in Series C funding.
The round was led by Zola Global and Greenoaks Capital with participation from Jackson Square Ventures, Olive Tree Capital, and others.
The company, which has raised a total of $73m to date, intends to use the funds for geographic expansion into new markets across the U.S. and deliver new products for chronic and complex therapeutic areas.
Founded in 2015 by Matt Gamache-Asselin, CEO, Alto Pharmacy is a patient-centric digital pharmacy that provides same-day, free delivery, seven days a week for prescriptions, offering cost transparency, personalized in-app and phone support, and real-time coordination with doctors and insurance companies.
It currently specializes in dermatology, fertility, biologics and HIV and will now deliver to patients in autoimmune (RA), endocrinology (diabetes), and cardio (heart disease).
The company, which also has offices in Denver, plans to roll out new delivery locations beyond San Francisco and Southern California and introduce mail-order services for patients outside of major metro areas. Alto is also broadening its services for complex and chronic conditions requiring specialty drug therapies.